Acadia Pharma (NASDAQ: ACAD) reported Q4 EPS of ($0.26), $0.01 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $136.5 million versus the consensus estimate of $134.23 million.

GUIDANCE:

Acadia Pharma sees FY2023 Nuplazid sales of $520-530 million, versus the consensus of $569 million.

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.